- Home
- SGMT vs ANIX Comparison
SGMT vs ANIX Comparison
Compare SGMT & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- ANIX
- Stock Information
- Founded
- SGMT 2006
- ANIX 1982
- Country
- SGMT United States
- ANIX United States
- Employees
- SGMT N/A
- ANIX N/A
- Industry
- SGMT
- ANIX Biotechnology: Pharmaceutical Preparations
- Sector
- SGMT
- ANIX Health Care
- Exchange
- SGMT Nasdaq
- ANIX Nasdaq
- Market Cap
- SGMT 93.7M
- ANIX 101.4M
- IPO Year
- SGMT 2023
- ANIX 1987
- Fundamental
- Price
- SGMT $5.18
- ANIX $3.17
- Analyst Decision
- SGMT Strong Buy
- ANIX Strong Buy
- Analyst Count
- SGMT 5
- ANIX 2
- Target Price
- SGMT $21.60
- ANIX $8.50
- AVG Volume (30 Days)
- SGMT 772.8K
- ANIX 123.4K
- Earning Date
- SGMT 11-13-2024
- ANIX 11-19-2024
- Dividend Yield
- SGMT N/A
- ANIX N/A
- EPS Growth
- SGMT N/A
- ANIX N/A
- EPS
- SGMT N/A
- ANIX N/A
- Revenue
- SGMT $2,000,000.00
- ANIX N/A
- Revenue This Year
- SGMT N/A
- ANIX N/A
- Revenue Next Year
- SGMT N/A
- ANIX N/A
- P/E Ratio
- SGMT N/A
- ANIX N/A
- Revenue Growth
- SGMT N/A
- ANIX N/A
- 52 Week Low
- SGMT $2.25
- ANIX $2.15
- 52 Week High
- SGMT $20.71
- ANIX $5.13
- Technical
- Relative Strength Index (RSI)
- SGMT 47.83
- ANIX 44.19
- Support Level
- SGMT $5.61
- ANIX $3.07
- Resistance Level
- SGMT $6.40
- ANIX $4.20
- Average True Range (ATR)
- SGMT 0.52
- ANIX 0.32
- MACD
- SGMT -0.10
- ANIX -0.05
- Stochastic Oscillator
- SGMT 17.57
- ANIX 6.64
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.